Do not leave your abstract submission until the last moment. AdPha are not responsible for any technical issues, including those that may arise from high system usage in the final hours of the abstract submission portal being open.
If you do not receive a confirmation email, your abstract has not been submitted.
Abstract guidelines
This information is designed to assist you in preparing an abstract for Medicines Management 2025. Please read this information together with the Abstract review criteria, against which your abstract will be reviewed.
WHAT IS AN ABSTRACT?
An abstract is a short statement that gives the reader a comprehensive yet concise understanding of your work. Your work could be research, a pharmacy practice project, or a case study.
Your abstract should tell readers what you are going to present and should ignite their interest about your work. Based on your abstract, if accepted, the reader may decide to attend your presentation, visit your poster, or contact you for more information.
WHO IS YOUR AUDIENCE?
Your abstract will have two main audiences:
Conference delegates: pharmacists, technicians, pharmacy interns, students, conference exhibitors, who will use your abstract to select which sessions to attend or which posters to view.
Abstract reviewers: will complete a blind review of your abstract to assist the adherence to the submission criteria and assess the quality of your work. Abstract reviewers use the abstract review criteria in this process.
Please note individual feedback from abstract reviewers will not be provided to authors.
After the conference, your abstract will be made available in the Book of Abstracts which is available publicly online for a broader audience.
ABSTRACT SUBMISSION RULES AND REQUIREMENTS
The person responsible for submitting an abstract acknowledges that consent to submit and present has been obtained by all authors of the abstract
The author/s agree to allow publication of the abstract content in the Book of Abstracts and conference app
Abstract submissions will ONLY be accepted via the online abstract submission portal
Abstract submissions that do not conform to all abstract submission criteria will be excluded from consideration.
This includes the use of the listed subheadings and any identifying information such as hospitals or workplaces
Once an abstract has been submitted, no further changes can be made. If your abstract is left in draft format you can continue to edit your abstract up until the close of abstract submissions at 11:59pm AEST Wednesday 2 July. After this, NO changes can be made to abstracts and no further abstracts can be submitted.
Please note that abstracts left in draft at the close of submissions are not considered a submittedabstract
This includes the listed authors on the abstract and author affiliations
Abstracts that contain identifiable information will not be considered for review
There can only be one presenting author for each abstract submission/presentation.
The presenting author must be an author listed on the original abstract submission. No changes can be made to listed authors after the close of abstract submissions 11:59pm AEST Wednesday 2 July)
You will be asked to enter the presenting author’s contact details, affiliation information, abstract title, presentation (oral or poster), additional or all author(s), at the time of submission.
Affiliation refers to the institute that each author belongs to, in relation to the abstract being submitted.
If submitting more than one abstract, each abstract must be submitted under the name of the presenting author.
The presenting author is invited to indicate their preference for oral or poster presentation only (or either). However, the final decision is that of the scientific program committee and will be solely determined by the quality and suitability of the abstract.
You will be asked to select up to three (3) specialty practice areas that relate to your abstract from the following list:
Aboriginal and Torres Strait Islander Health
Aid and volunteering
Cardiology
Climate and health
Clinical trials
Compounding
Critical care
Dispensing and distribution
Education and educational visiting
Emergency medicine
General medicine
Geriatric medicine
Infectious diseases
Leadership and management
Medical specialties (other than those already listed)
Medication safety
Medicines information
Mental health
Nephrology
Neurology
Oncology and haematology
Paediatrics and neonatology
Pain management
Palliative care
Pharmacy informatics and technology
Research
Respiratory
Rural and remote
Surgery and perioperative medicine
Technician and assistants
Transitions of care and primary care
Voluntary assisted dying
Wellbeing
Women’s and Newborn health
All successful presenters (contributed paper oral presenters and poster presenters) must register and pay to attend the full conference by close of early bird, 11:59pm AEST Thursday 2 October 2025. Successful presenters who do not register to attend the full conference will have their presentation withdrawn.
AdPha student members who have an abstract accepted for MM2025 only need to register for the day of their presentation and not the full conference.
No changes can be made to an abstract (including listed authors or affiliations) after the close of abstract submissions
ABSTRACT CONTENT RULES AND REQUIREMENTS
Abstracts should describe work that has not previously been presented at an AdPha event with a national audience.
This includes virtual seminars, virtual branch symposia and entries in the Resident of the Year award
Publication or presentation of the work at another conference is not a criterion for exclusion.
Author details (including institutions, hospital names, or affiliations) MUST NOT appear in the abstract.
NOTE: if identifying details are included, the abstract will not be considered for review.
Abstracts must be no more than 300 words in length, including mandatory subheadings and references (if included) but excluding the title.
The abstract title must be no more than 15 words in length and clearly state the nature of the work.
Abstracts must include subheadings applicable to the category under which the abstract is being submitted (see Abstract submission categories below).
No tables, graphs, pictures or diagrams are permitted in the abstract.
Abbreviations should be avoided where possible. Any abbreviations used should be spelled out in full on first use.
Statistical results should conform with the uniform requirements for manuscripts submitted to biomedical journals.
References are not required but may be included. References should follow the reference citation guide.
NOTE: references, if included, will contribute to the total word count.
Abstract submission categories
For Medicines Management 2025, abstract submissions are welcome in the three categories:
Original research
Pharmacy practice
Case reports
During the abstract submission process, you will be asked to declare any ethical approvals or informed consent obtained via a check box (if applicable). These are summarised in the table below.
Abstract category
Ethics / informed consent
Original research
Need to be ethically approved (e.g., where patients and/or patient data is analysed) OR are exempt from ethical approval (e.g., systematic reviews, meta-analyses)
Pharmacy practice
Generally, do not need to be ethically approved. Projects are generally deemed exempt from ethics approval based on governance processes at institutions.
Case reports
Generally, require informed consent from the patient and/or family.
Please note, your response to this question does not influence your abstract review score but may be considered during the abstract selection process.
ORIGINAL RESEARCH (INCLUDES CLINICAL RESEARCH, MEDICINES USE EVALUATIONS, SYSTEMATIC REVIEWS AND META-ANALYSIS, PHARMACOECONOMIC ANALYSIS, ETC.)
Background: briefly describe the rationale for the study.
Aim/Objective(s): a one sentence statement of the main study objective(s).
Methods: include study design, methods, intervention.
Results: a summary of the main results including any relevant statistical analysis.
Discussion: the main conclusion/interpretation of the results which are supported by the data provided and a clear description of the impact of the work.
PHARMACY PRACTICE (INCLUDES QUALITY IMPROVEMENT PROJECTS, ADMINISTRATION PROJECTS, HEALTH PROFESSIONAL EDUCATION, MEDICATION SAFETY INITIATIVES, ETC.)
Background: briefly describe the background and rationale for service, program, problem, need, etc.
Objective(s): describe the concept, service, role, or situation.
Action (Method): describe the steps taken to identify and resolve a problem(s), implement change, or develop and implement the new program.
Evaluation: describe the evaluation process of the project and results of evaluation.
Discussion: describe the concept’s importance and impact on current and/or future practice
CASE REPORTS
Objective: briefly describe the rationale for the case report.
Clinical Features: relevant demographic information, medical history, presenting problems and diagnoses.
Literature review: briefly examine current literature relating to or surrounding the case report.
Pharmacist Interventions, Case Progress and Outcomes: these may be presented together or separately and should detail the pharmacist’s role in the case.
Discussion: outlining lessons learnt and/or implications/importance of the case report on pharmacy practice.
Test your abstract before submitting it. Ask someone else to read it and to tell you what your work was about. It is a good idea to get someone who is not familiar with the work/research being described to test read your abstract.
Have you proofread your abstract several times? Check for spelling and grammatical errors, and logical understanding. Reading your abstract aloud can help you detect errors that eyes can miss.
Have you ensured there is no identifying material in your abstract?
Have you received approval from your workplace to submit your abstract with their affiliations? (Where applicable).
Have you included all abstract authors in your submission?
Have you typed your email address correctly in the abstract submission portal? This is where all correspondence will be sent.
Have you clicked SUBMIT and received email confirmation that your abstract has been submitted? Any abstract left in DRAFT after the close of abstract submissions will not be accepted for review.
